NeurologyLive® Brain Games: December 25, 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neurology news in 2022.

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.

Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.

This week's questions have the theme of neurology news in 2022.

Click here to check out the prior iterations of Brain Games.

Interested in submitting quiz questions? Contact our managing editor, Matt Hoffman, via email: mhoffman@neurologylive.com.

Earlier this year, daridorexant was approved by the FDA as a treatment for which of the following conditions?


In 2022, Biogen and Eisai's investigational agent lecanemab gained traction as a promising treatment for Alzheimer disease, and could become the second therapy approved for AD since aducanumab (Aduhelm; Biogen). The last approval in AD prior to aducanumab was which drug?


In September, the FDA made a landmark decision to grant approval to Amylyx Pharmaceuticals' AMX0035 (Relyvrio) for the treatment of amyotrophic lateral sclerosis (ALS). It was set to decide on another ALS hopeful this coming January, but extended the review period, tofersen. Which genetic cause of ALS does tofersen target?


How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!

How many questions did you get correct?

One
Two
Three
Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.